ATE133075T1 - Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel - Google Patents

Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel

Info

Publication number
ATE133075T1
ATE133075T1 AT88907537T AT88907537T ATE133075T1 AT E133075 T1 ATE133075 T1 AT E133075T1 AT 88907537 T AT88907537 T AT 88907537T AT 88907537 T AT88907537 T AT 88907537T AT E133075 T1 ATE133075 T1 AT E133075T1
Authority
AT
Austria
Prior art keywords
angiogenin
antibodies
immunotherapeutic agents
angiogenesis
fragment
Prior art date
Application number
AT88907537T
Other languages
English (en)
Inventor
James W Fett
Bert L Vallee
Edward M Alderman
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE133075T1 publication Critical patent/ATE133075T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88907537T 1987-08-06 1988-08-05 Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel ATE133075T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/083,231 US4853219A (en) 1987-08-06 1987-08-06 Antibodies to angiogenin: immunotherapeutic agents

Publications (1)

Publication Number Publication Date
ATE133075T1 true ATE133075T1 (de) 1996-02-15

Family

ID=22177021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88907537T ATE133075T1 (de) 1987-08-06 1988-08-05 Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel

Country Status (13)

Country Link
US (1) US4853219A (de)
EP (1) EP0436526B1 (de)
JP (1) JPH02504512A (de)
KR (1) KR920005691B1 (de)
AT (1) ATE133075T1 (de)
AU (1) AU618024B2 (de)
CA (1) CA1341425C (de)
DE (1) DE3854926T2 (de)
DK (1) DK29490A (de)
ES (1) ES2015349A6 (de)
GR (1) GR1000430B (de)
PT (1) PT88314A (de)
WO (1) WO1989000862A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520914A (en) * 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
FR2623509B1 (fr) * 1987-11-19 1990-04-20 Centre Nat Rech Scient Proteine de 17 kd a action angiogenique, son procede d'isolement a partir de lait de mammiferes, compositions therapeutiques la contenant, procede de detection et/ou de dosage et reactifs immunologiques de detection et de dosage des angiogenines de mammiferes, de leurs homologues et de leurs fragments
US6929907B2 (en) * 1999-12-31 2005-08-16 North Carolina State University Methods and compositions for determining the purity of chemically synthesized nucleic acids
RU2197263C1 (ru) * 2001-05-16 2003-01-27 Московский областной научно-исследовательский клинический институт Способ лечения ран и язвенных дефектов
AU2002319223A1 (en) 2001-06-13 2002-12-23 Osteopep-Pharma Gmbh Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
US7718369B2 (en) * 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2648947A1 (en) * 2006-04-10 2007-11-15 Fusion Antibodies Limited Therapy targeting cathepsin s

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229531A (en) * 1978-12-29 1980-10-21 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4229532A (en) * 1978-12-29 1980-10-21 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4273871A (en) * 1980-03-03 1981-06-16 Monsanto Company Production of angiogenic factor by cell culture
DE3110560A1 (de) * 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
DE3381236D1 (de) * 1982-11-30 1990-04-05 Univ Manchester Produktion von angiogenen faktoren.
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
US4503038A (en) * 1983-02-25 1985-03-05 The Regents Of The University Of California Extracellular nonmitogenic angiogenesis factor and method of isolation thereof from wound fluid
US4699788A (en) * 1984-08-20 1987-10-13 Trustees Of Boston University Angiogenic factor methods of extraction and method for producing angiogenesis
US4727137A (en) * 1985-04-17 1988-02-23 President And Fellows Of Harvard College Purified protein having angiogenic activity and methods of preparation
IL81650A0 (en) * 1986-02-24 1987-09-16 Robapharm Ag Purified human angiogenic factor,method for its preparation and pharmaceutical preparations

Also Published As

Publication number Publication date
EP0436526A1 (de) 1991-07-17
DK29490A (da) 1990-03-30
DE3854926T2 (de) 1996-05-30
KR920005691B1 (ko) 1992-07-13
AU618024B2 (en) 1991-12-12
AU2316688A (en) 1989-03-01
US4853219A (en) 1989-08-01
DE3854926D1 (de) 1996-02-29
CA1341425C (en) 2003-03-18
EP0436526A4 (de) 1990-08-20
KR890701130A (ko) 1989-12-19
ES2015349A6 (es) 1990-08-16
DK29490D0 (da) 1990-02-05
PT88314A (pt) 1989-06-30
WO1989000862A1 (en) 1989-02-09
EP0436526B1 (de) 1996-01-17
GR1000430B (el) 1992-07-30
JPH02504512A (ja) 1990-12-20

Similar Documents

Publication Publication Date Title
DE69024659D1 (de) Harnwegstumor-assoziiertes antigen, verwendung von antigenen untereinheiten und nachweisverfahren
NO934777L (no) Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje
NO302176B1 (no) Fremgangsmåte for fremstilling av et monoklonalt antistoff og et antigen
ATE45285T1 (de) Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren.
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
ATE133075T1 (de) Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel
AU525403B2 (en) Purified antigen
FI922017A0 (fi) Immunbestaemningar och monoklonala antikroppar foer protrombinaktiveringspeptider och degradations- produkter av dessa.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
DE69026875D1 (de) Immunobestimmung von menschlichem osteocalcin, reagenz und satz dafür
ATE87941T1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
EP0323802A3 (de) Gegen Lungenkrebs gerichtete monoklonale Antikörper und Zelloberflächenantigen davon
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
CA2054689A1 (en) An immunoassay method for determining the specificity of binding of a monoclonal antibody to an antigen
NO883854D0 (no) Monoklonalt antistoff og fremgangsmaate for dets fremstilling.
DK329789A (da) Monoklonalt antistof
ATE79475T1 (de) Verfahren zur bestimmung von immunoglobulin-aprotease.
NO881905L (no) Monoklonalt antistoff til selektiv immunologisk bestemmelse av intakt prokollagen peptid (type iii) og prokollagen (type iii) i kroppsvaesker.
DE69114546D1 (de) Neue Verwendung für einen monoklonalen Antikörper.
DE3478346D1 (en) Method for assaying basic fetoprotein and reagent therefor
ATE92081T1 (de) Tumorassoziiertes antigen.
ATE86261T1 (de) Tumorassoziiertes antigen.
AU573748B2 (en) Monoclonal antibody to cancer procoagulant and immunoassay